

Hyun-Woong Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5725835/publications.pdf>

Version: 2024-02-01

88
papers

1,969
citations

377584

21
h-index

312153

41
g-index

97
all docs

97
docs citations

97
times ranked

3317
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBsAg Seroclearance. <i>Digestive Diseases and Sciences</i> , 2022, 67, 321-328.	1.1	5
2	External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. <i>Cancers</i> , 2022, 14, 711.	1.7	1
3	Ca ²⁺ /Calmodulin-Dependent Protein Kinase II Inhibits Hepatitis B Virus Replication from cccDNA via AMPK Activation and AKT/mTOR Suppression. <i>Microorganisms</i> , 2022, 10, 498.	1.6	6
4	Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir. <i>Scientific Reports</i> , 2022, 12, 4382.	1.6	0
5	Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 1729.	1.0	2
6	Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report. <i>Journal of Liver Cancer</i> , 2022, 22, 84-90.	0.3	1
7	Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia. <i>Journal of Clinical Medicine</i> , 2022, 11, 1451.	1.0	0
8	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190.	1.2	8
9	Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea. <i>Investigational New Drugs</i> , 2021, 39, 260-268.	1.2	19
10	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 157-174.	4.5	74
11	Current Status of Therapeutic Choice and Feasibility for Patients with Hepatocellular Carcinoma Aged ≥ 70 Years: A Nationwide Cancer Registry Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 321-332.	1.8	6
12	Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2021, 21, 216.	0.8	9
13	Risk of hepatocellular carcinoma after spontaneous and nucleos(t)ide analogue induced hepatitis B surface antigen seroclearance. <i>Journal of Clinical Oncology</i> , 2021, 39, e16162-e16162.	0.8	0
14	The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476.	1.8	2
15	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	1.0	4
16	Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 919-927.	1.9	7
17	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	0.8	4
18	Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 116-124.	0.2	63

#	ARTICLE	IF	CITATIONS
19	Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892.	1.7	6
20	Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5628.	1.0	1
21	The HBV Core Protein and Core Particle Both Bind to the PPIase Par14 and Par17 to Enhance Their Stabilities and HBV Replication. <i>Frontiers in Microbiology</i> , 2021, 12, 795047.	1.5	10
22	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	1.1	3
23	Prognostic Factors of Radiofrequency Ablation plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis. <i>International Journal of Hepatology</i> , 2020, 2020, 1-8.	0.4	3
24	Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1052-1060.	1.0	7
25	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	1.9	43
26	An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases. <i>Journal of Virology</i> , 2020, 94, .	1.5	22
27	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	6.1	20
28	Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1612.	1.7	4
29	Human liver CD8+ MAIT cells exert TCR/MR1-independent innate-like cytotoxicity in response to IL-15. <i>Journal of Hepatology</i> , 2020, 73, 640-650.	1.8	35
30	Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance. <i>BMC Gastroenterology</i> , 2020, 20, 113.	0.8	7
31	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 411-429.	4.5	66
32	Should physicians go out of the way to differentiate between acute hepatitis B and acute exacerbation of chronic hepatitis B?. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 180-182.	4.5	0
33	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , 2019, 8, 5023-5032.	1.3	25
34	Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. <i>Cancers</i> , 2019, 11, 425.	1.7	8
35	Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. <i>Oncologist</i> , 2019, 24, e653-e661.	1.9	16
36	Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2019, 25, 4959-4969.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Tumor Necrosis Factor-producing T-regulatory Cells Are Associated With Severe Liver Injury in Patients With Acute Hepatitis A. <i>Gastroenterology</i> , 2018, 154, 1047-1060.	0.6	22
38	Innate-like Cytotoxic Function of Bystander-Activated CD8+ T Cells Is Associated with Liver Injury in Acute Hepatitis A. <i>Immunity</i> , 2018, 48, 161-173.e5.	6.6	144
39	Selective deletion of hepatocyte platelet-derived growth factor receptor α and development of liver fibrosis in mice. <i>Cell Communication and Signaling</i> , 2018, 16, 93.	2.7	17
40	Seroepidemiology of Hepatitis Viruses and Hepatitis B Genotypes of Female Marriage Immigrants in Korea. <i>Yonsei Medical Journal</i> , 2018, 59, 1072.	0.9	4
41	Treatment and Surveillance of Hepatocellular Carcinoma in Elderly Patient. <i>Journal of Liver Cancer</i> , 2018, 18, 103-114.	0.3	0
42	Shear Wave Liver Elastography with a Propagation Map: Diagnostic Performance and Inter-Observer Correlation for Hepatic Fibrosis in Chronic Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 1355-1363.	0.7	30
43	Inverse Psoriasis with Autoimmune Hepatitis. <i>Annals of Dermatology</i> , 2017, 29, 820.	0.3	0
44	Current status and strategies for the control of viral hepatitis A in Korea. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 196-204.	4.5	21
45	Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 1010-1017.	0.7	3
46	Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. <i>Gut and Liver</i> , 2017, 11, 721-727.	1.4	13
47	Comparative Analysis of Liver Injury-Associated Cytokines in Acute Hepatitis A and B. <i>Yonsei Medical Journal</i> , 2016, 57, 652.	0.9	6
48	The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine. <i>Journal of Medical Virology</i> , 2016, 88, 820-827.	2.5	1
49	An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys). <i>Medicine (United States)</i> , 2016, 95, 10784314.	0.7	1
50	Endovascular management of hemosuccus pancreaticus, a rare case report of gastrointestinal bleeding. <i>BMC Gastroenterology</i> , 2016, 16, 5.	0.8	21
51	Feasibility of α -fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 46-53.	0.7	12
52	Nonzero Risk of Hepatocellular Carcinoma Even after Sustained Virological Response. <i>Gut and Liver</i> , 2016, 10, 661-662.	1.4	2
53	Virtual Reality Therapy for the Treatment of Alcohol Dependence: A Preliminary Investigation With Positron Emission Tomography/Computerized Tomography. <i>Journal of Studies on Alcohol and Drugs</i> , 2015, 76, 620-627.	0.6	43
54	Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naïve Chronic Hepatitis B Patients with a Partial Virological Response. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5348-5356.	1.4	7

#	ARTICLE	IF	CITATIONS
55	Liver injury in acute hepatitis A is associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis. <i>Gut</i> , 2015, 64, 1303-1313.	6.1	38
56	Clinical usefulness of international normalized ratio calibration of prothrombin time in patients with chronic liver disease. <i>International Journal of Hematology</i> , 2015, 102, 163-169.	0.7	12
57	Clinical Factors and Viral Load Influencing Severity of Acute Hepatitis A. <i>PLoS ONE</i> , 2015, 10, e0130728.	1.1	21
58	Highly effective peginterferon α -2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 125.	4.5	4
59	Comparative Genotype Analysis of Hepatitis A Virus: Two One-Year Studies in South Korea in 2002 and 2011. <i>Journal of Bacteriology and Virology</i> , 2014, 44, 252.	0.0	2
60	Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 231.	0.7	19
61	Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1049-1055.	1.4	6
62	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	1.4	26
63	Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy. <i>Journal of Clinical Virology</i> , 2014, 60, 313-316.	1.6	21
64	Colonic Mucosal Immune Activity in Irritable Bowel Syndrome: Comparison with Healthy Controls and Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1001-1011.	1.1	49
65	Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 267.	4.5	5
66	Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 345.	4.5	1
67	Extended hemangioma from pharynx to esophagus that could be misdiagnosed as an esophageal varix on endoscopy. <i>Digestive Endoscopy</i> , 2013, 25, 626-629.	1.3	5
68	Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients. <i>International Journal of Cancer</i> , 2013, 133, 408-415.	2.3	33
69	Antibody-Secreting Cells with a Phenotype of Ki-67low, CD138high, CD31high, and CD38high Secrete Nonspecific IgM during Primary Hepatitis A Virus Infection. <i>Journal of Immunology</i> , 2013, 191, 127-134.	0.4	16
70	Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 36.	4.5	22
71	Important predictor of mortality in patients with end-stage liver disease. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 105.	4.5	85
72	Systemic Amyloidosis Manifested by Gastric Outlet Obstruction. <i>Clinical Endoscopy</i> , 2013, 46, 579.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Simultaneous Emergence of Entecavir Resistance Mutations in a Nucleoside-Naive Chronic Hepatitis B Patient. <i>Intervirology</i> , 2012, 55, 380-384.	1.2	8
74	The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 220-227.	1.1	199
75	Revision and update on clinical practice guideline for liver cirrhosis. <i>The Korean Journal of Hepatology</i> , 2012, 18, 1.	1.5	120
76	Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2012, 18, 6277.	1.4	34
77	Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 415-421.	3.6	107
78	The Frequency and Risk Factors of Colorectal Adenoma in Health-Check-up Subjects in South Korea: Relationship to Abdominal Obesity and Age. <i>Gut and Liver</i> , 2010, 4, 36-42.	1.4	18
79	M1613: Comparison of the Efficacy of Lansoprazole and Lansoprazole Plus Ecabet Sodium in the Treatment of Iatrogenic Gastric Ulcers After Endoscopic Submucosal Dissection. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB267-AB268.	0.5	1
80	A case of hypereosinophilic syndrome presenting with intractable gastric ulcers. <i>World Journal of Gastroenterology</i> , 2009, 15, 6129.	1.4	2
81	Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study. <i>Gut and Liver</i> , 2009, 3, 20-25.	1.4	5
82	Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir. <i>Antiviral Therapy</i> , 2009, 14, 705-712.	0.6	26
83	Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 729-735.	1.4	19
84	Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B. <i>Intervirology</i> , 2008, 51, 293-298.	1.2	8
85	Clinical Features and Treatment Outcomes of Upper Gastrointestinal Bleeding in Patients with Cirrhosis. <i>Journal of Korean Medical Science</i> , 2008, 23, 635.	1.1	24
86	Anti-hepatitis A virus seroprevalence among patients with chronic viral liver disease in Korea. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 923-926.	0.8	16
87	Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2007, 110, 129-137.	2.0	102
88	The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 447-455.	0.6	31